Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Vesicular stromatitis virus (VSV)

A virus and tumor technology, applied in the direction of viruses, viral peptides, viruses/phages, etc., can solve the problem of not testing the anti-VSV cytotoxic activity

Inactive Publication Date: 2004-05-12
VIRUSTA BIOLOGICAL
View PDF8 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Anti-VSV cytotoxic activity in other cell types was not tested

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vesicular stromatitis virus (VSV)
  • Vesicular stromatitis virus (VSV)
  • Vesicular stromatitis virus (VSV)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0117] Example 1: PKR negative cells are susceptible to VSV infection.

[0118] in vivo experiment

[0119] Initial experiments are aimed at identifying viruses capable of infecting PKR- / - animals and cells. A PKR-deficient mouse strain (35, incorporated herein by reference) was generated using a homologous recombination strategy and tested for their ability to resist viral infection. Since these mice are PKR- / -, they should be susceptible to virus infection. Several virus species were administered to PKR null animals at a range of concentrations.

[0120] Infection of PKR-deficient mice

[0121] PKR-null mice were generated using conventional knockout techniques (Abraham, N., et al., J Biol Chem, 1999. 274:5953-5962). Groups of 5 female mice, three months old or older, were infected intranasally with varying amounts of herpetic stomatitis virus (Indiana strain). Age-matched wild-type animals were infected in parallel and both series of animals were monitored daily for si...

Embodiment 2

[0124] Example 2: Selective killing of tumor cells with VSV

[0125] In vitro experiments

[0126] Several tumor cell lines were randomly selected at the Ottawa Regional Cancer Center and tested for their susceptibility to VSV infection. Primary fibroblast cultures from healthy adult volunteers or primary bone marrow samples from healthy donors were used as control cells.

[0127] Infection of tumor cells with VSV

[0128] As a first test of the oncolytic properties of VSV, virus yield and cytopathic effect after overnight incubation with VSV were assessed. Cell monolayers were incubated with Indiana strain VSV at a multiplicity of infection (moi) of 0.1 plaque forming units (pfu). After allowing the virus to adsorb for 30 minutes at 37 degrees, the culture was rinsed thoroughly with phosphate buffered saline (PBS) and incubated for an additional 18 hours at 37 degrees. At this point, cytopathic effects (cpe) were examined under a microscope and photographed. The 18-hour ...

Embodiment 3

[0139] Example 3: Killing Tumor Cells in Mixed Cultures

[0140] Human fibroblasts and 293T tumor cells were co-cultured at a ratio of 50:50. Since 293T cells express a macromolecular T antigen that is not present in normal cells, the two cell types can be distinguished by immunofluorescence.

[0141] Cultures were infected in this experiment at a moi of 0.1 pfu / cell and infection was allowed in the presence or absence of interferon. At 0, 18 and 24 hours (Figure 4) the cultures were fixed and stained with an antibody to the macromolecular T antigen (red nuclei) to detect 293T cells and DAPI (blue nuclei) to stain all cell types. Both cell types initially exhibit a spindle-shaped morphology with large oval nuclei. After 18 hours the number of 293T cells (red nuclei) decreased and many remaining 293T cells showed altered nuclear morphology. At 24 hours after infection, very few 293T cells were detected, and the few remaining 293T cells showed the characteristics of condensed...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterised by having low levels, or no PKR activity, or as being PKR- / -, STAT1- / - or both PKR- / - and STAT- / -. The virus is selected from the group consisting of Rhabdovirus and picornavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.

Description

[0001] This application claims the benefit of U.S. Provisional Application ________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ year September 17, the contents of which are incorporated herein by reference. [0002] The present invention relates to a novel method of cancer treatment. More specifically, the invention relates to viruses that selectively infect and inhibit the growth of tumor cells. Background of the invention [0003] The use of oncolytic bacteria or compositions of oncolytic bacteria to attack human and animal neoplasms is known. For example, European Patent 546 121, British Patent 1,587,244 and US Patent 3,192,116 disclose the use of non-pat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/00A61K35/76A61K35/766A61K38/00A61P35/00A61P35/02C07K14/145C12N7/00C12N7/02C12N7/04C12Q1/70
CPCC12N2760/20232C12N2760/20222C07K2319/00C12N2760/20221C07K2319/21A61K38/21C12N7/00A01K2267/0331C07K14/005C12N2760/20261C12N2760/20251A61K35/766A61P35/00A61P35/02A61K2300/00
Inventor J·C·贝尔N·索宁贝格D·F·斯托德尔E·G·布朗H·L·阿特金斯R·M·马里乌斯B·D·利克蒂S·B·诺勒斯
Owner VIRUSTA BIOLOGICAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com